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Background
The Holy Grail sought by all Bioprocess Cell Line Devel-
opment (CLD) groups is achieving high yields from easily-
cultured, robustly-growing cells in timelines measured in
weeks rather than months. As the first bottleneck in pro-
cess development, CLD must first birth its product for
upstream and downstream groups to initiate their own
reproductive cycles. To facilitate shortened CLD timelines,
scientists have turned to new technologies and automation
platforms. Emerging high-throughput instrumentation
such as Clonepix and Automated MicroBioreactors
(AMBR) have been enthusiastically integrated into stable
cell line generation platforms; however, application of
these methodologies among users is divergent.
In this study, we describe method development that is
part of an ongoing effort to create a vigorous, adaptable,
high-throughput cell line development platform, incorpor-
ating in-house VRC-DG44-CHO cells, expression vectors
with high-activity regulatory elements, and efficient selec-
tion and evaluation methods that result in early generation
of optimal-yielding, vigorous, stable cell lines. This study
was aimed toward a) evaluating early incorporation of
Clonepix technology to maximize transfectant pool
heterogeneity, b) identifying Clonepix fluorescence attri-
butes that increase the probability of high-productivity
clone isolation, c) evaluating and optimizing AMBR oper-
ating conditions to achieve process attributes comparable
to and predictive of medium-scale bioreactors, and
implementation of these practices for maximal results
with shortened timelines.
Materials and methods
Host Cell Line: Adherent, serum-dependent CHO-DG44
cells were adapted to grow in suspension in serum-free,
chemically defined production medium (ActiCHO P).
Suspension-adapted cells were cloned using semi-solid
clone CHO clone media and ClonePix II™ methodology.
Isolated clonal cultures were assessed for growth traits,
and the top 20 clones with fast growing profiles were
pooled to comprise the VRC CHO DG44 host cell line.
Expression plasmid: One VPPL-DHFR vector, present-
ing two open reading frames for concomitant expression
of heavy and light chains under distinct CMV promoters
with DHFR expression in cis for selection for CHO
DG44 cells, was assembled. Two heterologous enhancer
elements have been inserted upstream of each CMV pro-
moter to augment protein expression levels.
Cells were transfected with pre and post-optimized ver-
sions of VPPL-DHFR vector expressing mAb. Stable pools
generated from traditional large pool (LP) selections were
seeded at 1000 cells/mL in semi-solid media, while direct
cloning (DC) cells at 48 hours post-transfection were
seeded at 5000 cells/mL.
Results
To streamline and maintain medium composition homo-
geneity from cell line development all the way up to pro-
duction scale, we adapted our host cell CHO DG44 line
to Acti-CHO P production medium by gradually weaning
the cells from serum-containing medium to the ActiCHO
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SM medium, a leaner sibling of ActiCHO P production
medium. When cells were completely serum free (theore-
tically calculated) and further passaged in ActiCHO SM
medium, the cell doubling time was >57 h. To select a
rapidly-cycling population, cells growing in Acti-CHO
SM medium were plated in Clonepix semisolid medium,
and individual clones were picked and seeded in 96 well
plates and expanded to shake flasks. Top 20 clones with
doubling times of 24 + 6 h were pooled in two pools,
each of which demonstrated transfection efficiences of
> 50% and doubling times of 24 + 4 h.
To reduce the cell line generation timeline, we evalu-
ated Clonepix II technology implemention within 48 h
post transfection compared to 3 weeks for pool genera-
tion followed by seeding semi-solid medium. Data sup-
ported that direct cloning in semisolid medium with
100 nM MTX at 48 hours post-transfection could reduce
the CLD timeline to <3 months. Observable morpholo-
gies of the clones seeded 48 h post transfection were
comparable to those of cells seeded from traditional
work flow (1.0). We have also evaluated whether there is
any correlation between Clonepix attributes and eventual
high-producing clones.
Our data indicated that Clonepix attribute such as
normalized external fluorescence area to white light area
were predictive of productivity at 96-well stage and
beyond. Further clones were expanded from 96-well
plates to shake flasks by down-selecting at each stage
based either on confluence (select clones > 30% conflu-
ence) or titer. Our initial experiments with AMBR bior-
eactors for down-selecting the clones examined
scalability to production scale bioreactors, used baseline
operating conditions of aeration 0.11 slpm, agitation
700 rpm (up draft) with a calculated tip speed of
0.417 m/sec and gas velocity of 0.14 m/sec and main-
tains a KLa of 3 sec-1 for a 15 mL working volume, and
resulted in inability to maintain DO at set 50% after day
5, indicating that the selected clones have high oxygen
demands. Experiments to optimize operating conditions
by changing the aeration and agitation rates to meet the
high OUR (OTR) revealed that aeration of 0.27 slpm,
agitation rate of 1000 rpm (down draft) with a calcu-
lated tip speed of 0.596 m/sec and gas velocity of
0.34 m/sec maintained a KLa of 7 sec-1, supplying the
oxygen demand of these culture and maintaining DO at
the 50% setpoint. Our top clones in optimized AMBR
bioreactors produced about 2.6 g/L in a 17-day fed
batch culture (Figure 1).
Conclusions
Our data suggested that Clonepix attributes such as
External fluorescence Area (EFA), White Light Area
(WLA), and normalized EFA to WLA were predictive of
productivity at the 96-well stage and beyond. Early
AMBR optimization studies revealed that down-draft agi-
tation maintained the dissolved oxygen (DO) concentra-
tion at higher cell densities than updraft agitation,
maintained DO in the range of 50+5%, and resulted in
clones with improved titers that were comparable to and
predictive of those from 3 L bioreactors. Overall, our first
generation integrated platform, comprising preadaptation
of the host cell line to production medium prior to
Figure 1 Data from various stages of the CLD process flow.
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transfection, ClonePix technology introduction early in
the process flow (48 hours post-transfection), and clone
screening in AMBR for down-selection to the top three
to five clones for 3 L bioreactor evaluation enabled us to
generate stable clones at the AMBR stage with productiv-
ities of 2.5 to 3 g/L in a 14-day, fed-batch process. This
integrated strategy reduced the CLD timeline to three
months from vector generation to final clone selection.
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